US Bancorp DE Has $902,000 Stock Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

US Bancorp DE lowered its position in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 7.9% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 45,373 shares of the biopharmaceutical company’s stock after selling 3,885 shares during the quarter. US Bancorp DE’s holdings in Catalyst Pharmaceuticals were worth $902,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in CPRX. Pacer Advisors Inc. increased its position in Catalyst Pharmaceuticals by 130,918.8% in the 2nd quarter. Pacer Advisors Inc. now owns 2,967,575 shares of the biopharmaceutical company’s stock valued at $45,968,000 after acquiring an additional 2,965,310 shares in the last quarter. Janus Henderson Group PLC raised its stake in shares of Catalyst Pharmaceuticals by 139.5% during the first quarter. Janus Henderson Group PLC now owns 2,726,388 shares of the biopharmaceutical company’s stock worth $43,445,000 after buying an additional 1,587,794 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Catalyst Pharmaceuticals by 12.1% during the first quarter. Vanguard Group Inc. now owns 7,980,661 shares of the biopharmaceutical company’s stock worth $127,212,000 after buying an additional 860,244 shares during the last quarter. Kennedy Capital Management LLC raised its stake in shares of Catalyst Pharmaceuticals by 101.1% during the first quarter. Kennedy Capital Management LLC now owns 1,061,704 shares of the biopharmaceutical company’s stock worth $16,924,000 after buying an additional 533,802 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Catalyst Pharmaceuticals by 15.2% during the second quarter. Renaissance Technologies LLC now owns 2,175,727 shares of the biopharmaceutical company’s stock worth $33,702,000 after buying an additional 287,300 shares during the last quarter. Institutional investors and hedge funds own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Up 2.9 %

Shares of CPRX stock opened at $23.93 on Friday. The company’s fifty day simple moving average is $20.74 and its 200-day simple moving average is $18.06. The firm has a market cap of $2.84 billion, a PE ratio of 44.32, a P/E/G ratio of 3.47 and a beta of 0.75. Catalyst Pharmaceuticals, Inc. has a 12 month low of $12.27 and a 12 month high of $24.27.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported $0.52 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.13. The business had revenue of $122.71 million for the quarter, compared to analyst estimates of $111.76 million. Catalyst Pharmaceuticals had a net margin of 15.69% and a return on equity of 27.77%. On average, equities analysts predict that Catalyst Pharmaceuticals, Inc. will post 1.82 earnings per share for the current fiscal year.

Insider Transactions at Catalyst Pharmaceuticals

In other news, Director David S. Tierney sold 15,000 shares of the business’s stock in a transaction on Wednesday, August 21st. The shares were sold at an average price of $20.10, for a total value of $301,500.00. Following the sale, the director now owns 348,874 shares of the company’s stock, valued at $7,012,367.40. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Catalyst Pharmaceuticals news, insider Steve Miller sold 150,000 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $20.35, for a total transaction of $3,052,500.00. Following the sale, the insider now directly owns 675,124 shares of the company’s stock, valued at approximately $13,738,773.40. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director David S. Tierney sold 15,000 shares of the company’s stock in a transaction on Wednesday, August 21st. The stock was sold at an average price of $20.10, for a total transaction of $301,500.00. Following the sale, the director now directly owns 348,874 shares in the company, valued at $7,012,367.40. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 11.00% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. Citigroup boosted their price target on shares of Catalyst Pharmaceuticals from $27.00 to $31.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a report on Friday. Truist Financial boosted their price objective on shares of Catalyst Pharmaceuticals from $25.00 to $30.00 and gave the company a “buy” rating in a report on Friday, August 9th. Finally, StockNews.com upgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Friday, August 9th. Six investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Catalyst Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $29.50.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.